B6-Alms1-del MASH Models

At 6 weeks, B6-Alms1 mutant mice developed classic MASH symptoms under Western diet feeding, with symptoms including significant systemic metabolic disorders (such as obesity and hyperlipidemia) and severe steatosis, inflammation, hepatocytic ballooning, and mild liver fibrosis. By 8 weeks, the mutant mice became obese and hyperglycemic, while fatty liver took 20 weeks to develop.


Data Validation

1. Body Weight

图片1.png

Figure1. The B6-Als1-del MASH model gained weight. Data are presented as Mean±SD. n=5-15.


2. Liver Morphology

图片2.png

Figure 2. After 6 weeks of feeding, the B6-Alms1-del MASH mice exhibited a severe fatty liver phenotype. Data are presented as Mean±SD, n=5. ***, P<0.0001 by unpaired t test.


3. Plasma Chol and LDL-C

图片3.png

Figure 3. After 6 weeks of feeding, plasma cholesterol and LDL cholesterol levels were considerably increased in the B6-Alms1-del MASH model. Data are presented as Mean±SD. n=5-15. ****, p<0.00001 by one way ANOVA with Tukey’s post hoc test.


4. Liver TG and Chol

图片4.png

Figure 4. After 6 weeks of feeding, liver TG and total cholesterol levels were considerably increased in the B6-Alms1-del MASH model. Data are presented as Mean±SD. n=5-15. ****, p<0.01 by unpaired t test.


5. Plasma liver enzymes

图片5.png

Figure 5. After 6 weeks of feeding, plasma liver enzymes levels were considerably increased in the B6-Alms1-del MASH model. Data are presented as Mean±SD. n=5. ****, p<0.01 by unpaired t test.


6. Histopathology

image.png


Figure 6. At 21 weeks of age, B6-Alms1-del mice given conventional diet (CD) developed a fatty liver phenotype, but the score was only 4.2 and did not reach MASH levels. Following 6 weeks of Western diet (WD), B6-Alms1-del mice exhibited phenotypes of severe steatosis, inflammation, ballooning lesions, and moderate fibrosis. The NAS score was 6.0, and the fibrosis score was 1.6.


Efficacy data

1. Body Weight

图片7.png

Figure 7. MGL-3196 and Semaglutide significantly reduced body weight in B6-Alms1-del MASH model. Data are presented as Mean±SD. n=7. *,P<0.05;***,P<0.001;****,P<0.0001; by one way ANOVA with Tukey's post hoc test.


2. Blood Lipid levels

图片8.png

Figure 8. MGL-3196 and Semaglutide improved dyslipidemia and liver function in the B6-Alms1-del MASH model. Data are presented as Mean±SD. n=5-7. ***,P<0.001;****,P<0.0001; by one way ANOVA with Tukey's post hoc test.


3. Liver Enzymes Levels

图片9.png

Figure 9. MGL-3196 and Semaglutide improved the levels of liver enzymes ALT and AST in the B6-Alms1-del MASH model. Data are presented as Mean±SD. n=5-7. ***,P<0.001;****,P<0.0001; by one way ANOVA with Tukey's post hoc test.

TALK WITH OUR EXPERTS

GemPharmatech is committed to protecting and respecting your privacy, and we'll only use your personal information to administer your account and to provide the products and services you requested from us. From time to time, we would like to contact you about our products and services, as well as other content that may be of interest to you. If you consent to us contacting you for this purpose, please click below to say how you would like us to contact you:

In order to provide you with the content requested, we need to store and process your personal data. If you consent to us storing your personal data for this purpose, please click the checkbox below.

You can unsubscribe from these communications at any time. For more information on how to unsubscribe, our privacy practices, and how we are committed to protecting and respecting your privacy, please review our Privacy Policy.